89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the initiation of ENTRUST, a Phase 3 trial evaluating the efficacy, safety and tolerability of pegozafermin in patients with severe hypertriglyceridemia (SHTG).
https://finance.yahoo.com/news/89bio-initiates-phase-3-entrust-120000691.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.